GlaxoSmithKline PLC — Regulatory Filings 2017

Feb 21, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 20 February 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the ' Company ')

GlaxoSmithKline plc

(the Company )

Shares withheld or sold to meet tax liabilities

Following the vesting of the pre-tax awards granted in 2014 under the GlaxoSmithKline Deferred Annual Bonus Plan (DABP) on 16 February 2017 and as notified on 17 February 2017, the notifications that follow refle ct changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) in American Depositary Shares (ADSs) of the Company arising from the withholding of ADSs to meet tax liabilities.

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr M M Slaoui | |
| --- | --- | --- | --- |
| b) | Position/status | Chairman, Global Vaccines | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial instrument | GlaxoSmithKline plc American Depositary Shares
('ADSs') ISIN:
US37733W1053 | |
| b) | Nature of the transaction | The withholding of ADSs to meet tax liabilities further to the
vesting of awards granted in 2014 under the Company's 2009 Deferred
Annual Bonus Plan-Deferred Bonus and Matching Awards. | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | $40.57 | 9,237 (Deferred) |
| | | $40.57 | 3,249 (Matching) |
| d) | Aggregated information Aggregated volume Price | 1 2,486 $40.57 | |
| e) | Date of the transaction | 2017-02-16 | |
| f) | Place of the
transaction | n/a | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D E Troy | |
| --- | --- | --- | --- |
| b) | Position/status | SVP & General Counsel | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial instrument | GlaxoSmithKline plc American Depositary Shares
('ADSs') ISIN:
US37733W1053 | |
| b) | Nature of the transaction | The withholding of ADSs to meet tax liabilities further to the
vesting of awards granted in 2014 under the Company's 2009 Deferred
Annual Bonus Plan-Deferred Bonus and Matching Awards. | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | $40.57 | 3,280 (Deferred) |
| | | $40.57 | 1,208 (Matching) |
| d) | Aggregated information Aggregated volume Price | 4,488 $40.57 | |
| e) | Date of the transaction | 2017-02-16 | |
| f) | Place of the
transaction | n/a | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
20, 2017
By: VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break